Publications by authors named "Matthias Calamia"

Claim this Profile
B
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
Ivo Abraham, Matthias Calamia, Nimer Alkhatib, Marc Pondel, Karen MacDonald

J Med Econ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
Ivo Abraham, Matthias Calamia, Nimer Alkhatib, Marc Pondel, Karen MacDonald

J Med Econ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries.
Matthias Calamia, Ivo Abraham

Expert Opin Biol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not Yet.
Ivo Abraham, Matthias Calamia, Karen MacDonald

JAMA Netw Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of polatuzumab-bendamustine-rituximab tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL.
Matthias Calamia, Ali McBride, Ivo Abraham

J Med Econ· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities.
Briana M Choi, Rachel B Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi

J Med Econ· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis